Immuneonco Biopharmaceuticals (shanghai) Inc.
Clinical trials sponsored by Immuneonco Biopharmaceuticals (shanghai) Inc., explained in plain language.
-
New drug duo targets tough tumors in early trial
Disease control Not yet recruitingThis early-stage study is testing a new combination of two experimental drugs, IMM2510 and IMM01, in adults with advanced solid tumors that have worsened after at least one prior treatment. The main goals are to find a safe dose and see if the combination can shrink tumors. Resea…
Phase: PHASE1, PHASE2 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New hope for Tough-to-Treat lymphoma: major trial tests promising drug duo
Disease control Not yet recruitingThis study is testing whether adding a new drug called IMM0306 to a standard medication (lenalidomide) works better than lenalidomide alone for follicular lymphoma that has come back or isn't responding to treatment. It will involve about 198 patients who have already tried at le…
Phase: PHASE3 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC